BSX underperformed the Russell 1000 Growth Index in Q1 2026, falling 45.7% over the past year amid broader market volatility.
Boston Scientific Corporation (BSX) closed at $56.81 on May 19, 2026, reflecting a one-month decline of 12.42%. The drop followed weak quarterly results that contributed to a 45.71% loss over the past 52 weeks, underperforming broader market benchmarks.
The company’s market capitalization stood at $84.44 billion. In Q1 2026, the TCW Concentrated Large Cap Growth Fund reported an 11.75% net loss, trailing the Russell 1000 Growth Index’s 9.78% decline. Geopolitical tensions and AI concerns weighed on equity markets during the period.
Fund managers noted market broadening as a positive sign but acknowledged BSX’s struggles in a volatile environment.